Literature DB >> 10793317

Predicting how equipotent doses of chlorpromazine, haloperidol, sulpiride, raclopride and clozapine reduce locomotor activity in mice.

V M Simón1, A Parra, J Miñarro, M C Arenas, C Vinader-Caerols, M A Aguilar.   

Abstract

Distinguishing the specific effects of neuroleptics on one particular behaviour from its non-specific effects on motility is not easy. In this study, the effects of five neuroleptics on spontaneous motor activity were compared and the ED(50) values of these drugs to impair activity were calculated. Male and female mice were evaluated in an actimeter or in a shuttle-box used as an open field after the administration of chlorpromazine (0.4, 1.2, 3.6 mg/kg), haloperidol (0.1, 0.3, 0.9 mg/kg), raclopride (0.1, 0.3, 0.9 mg/kg), sulpiride (10, 30, 90 mg/kg) and clozapine (0.4, 1.2, 3.6 mg/kg), and two automatic and two observational activity measures were obtained. A very high correlation between automatic and observational measures, absence of sex differences, and a dose-dependent decrease of activity were observed with every compound. The results allow us to make accurate comparisons between these drugs in their potency in reducing spontaneous motor activity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10793317     DOI: 10.1016/s0924-977x(00)00070-5

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  23 in total

1.  Infralimbic D2 receptors are necessary for fear extinction and extinction-related tone responses.

Authors:  Devin Mueller; Christian Bravo-Rivera; Gregory J Quirk
Journal:  Biol Psychiatry       Date:  2010-12-01       Impact factor: 13.382

Review 2.  Regional differences in the action of antipsychotic drugs: implications for cognitive effects in schizophrenic patients.

Authors:  Richard J Beninger; Tyson W Baker; Matthew M Florczynski; Tomek J Banasikowski
Journal:  Neurotox Res       Date:  2010-04-08       Impact factor: 3.911

3.  Effects of haloperidol, clozapine, and quetiapine on sensorimotor gating in a genetic model of reduced NMDA receptor function.

Authors:  Gary E Duncan; Sheryl S Moy; Jeffery A Lieberman; Beverly H Koller
Journal:  Psychopharmacology (Berl)       Date:  2005-12-16       Impact factor: 4.530

4.  Evaluation of age and sex differences in locomotion and catalepsy during repeated administration of haloperidol and clozapine in adolescent and adult rats.

Authors:  Jenny L Wiley; Rhys L Evans
Journal:  Pharmacol Res       Date:  2008-08-22       Impact factor: 7.658

5.  A novel strategy for dissecting goal-directed action and arousal components of motivated behavior with a progressive hold-down task.

Authors:  Matthew R Bailey; Greg Jensen; Kathleen Taylor; Chris Mezias; Cait Williamson; Rae Silver; Eleanor H Simpson; Peter D Balsam
Journal:  Behav Neurosci       Date:  2015-06       Impact factor: 1.912

6.  Differential sensitivity to acute administration of Ritalin, apomorphine, SCH 23390, but not raclopride in mice selectively bred for hyperactive wheel-running behavior.

Authors:  J S Rhodes; T Garland
Journal:  Psychopharmacology (Berl)       Date:  2003-04-01       Impact factor: 4.530

7.  Ramelteon Improves Post-traumatic Stress Disorder-Like Behaviors Exhibited by Fatty Acid-Binding Protein 3 Null Mice.

Authors:  Yasushi Yabuki; Ibuki Takahata; Kazuya Matsuo; Yuji Owada; Kohji Fukunaga
Journal:  Mol Neurobiol       Date:  2017-05-17       Impact factor: 5.590

8.  Alcohol-induced behavioral changes in zebrafish: The role of dopamine D2-like receptors.

Authors:  Steven Tran; Amanda Facciol; Robert Gerlai
Journal:  Psychopharmacology (Berl)       Date:  2016-03-09       Impact factor: 4.530

9.  To breed or not to breed? Empirical evaluation of drug effects in adolescent rats.

Authors:  Jenny L Wiley; Rhys L Evans
Journal:  Int J Dev Neurosci       Date:  2008-11-08       Impact factor: 2.457

10.  The glycine transporter-1 inhibitor SSR103800 displays a selective and specific antipsychotic-like profile in normal and transgenic mice.

Authors:  Denis Boulay; Olivier Bergis; Patrick Avenet; Guy Griebel
Journal:  Neuropsychopharmacology       Date:  2010-01       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.